TCGA-BH-A0H3-01A-11R-A12P-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 64
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.540
- ANGIOGENESIS+0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.440
- HEDGEHOG_SIGNALING+0.370
- TGF_BETA_SIGNALING+0.360
- ANDROGEN_RESPONSE+0.320
- KRAS_SIGNALING_UP+0.300
- PROTEIN_SECRETION+0.280
- WNT_BETA_CATENIN_SIGNALING+0.270
- TNFA_SIGNALING_VIA_NFKB+0.210
Top 10 suppressed
- E2F_TARGETS-0.570
- G2M_CHECKPOINT-0.440
- OXIDATIVE_PHOSPHORYLATION-0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
- MYC_TARGETS_V2-0.390
- MTORC1_SIGNALING-0.370
- INTERFERON_ALPHA_RESPONSE-0.360
- GLYCOLYSIS-0.350
- DNA_REPAIR-0.330
- UV_RESPONSE_UP-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AR-A24T-01A-11R-A169-07 | — | A | 0.906 |
| 2 | TCGA-AR-A2LM-01A-11R-A180-07 | — | A | 0.893 |
| 3 | TCGA-BH-A1FH-01A-12R-A13Q-07 | — | A | 0.891 |
| 4 | TCGA-HD-7831-01A-11R-2132-07 | — | — | 0.887 |
| 5 | TCGA-E2-A1IO-01A-11R-A144-07 | — | A | 0.882 |
| 6 | TCGA-AR-A1AL-01A-21R-A12P-07 | — | A | 0.873 |
| 7 | TCGA-D8-A1JH-01A-11R-A13Q-07 | — | A | 0.866 |
| 8 | SRR6013569 | — | cohortMD2 | 0.858 |
| 9 | TCGA-EW-A1J2-01A-21R-A13Q-07 | — | A | 0.845 |
| 10 | TCGA-SY-A9G0-01A-12R-A38B-07 | — | — | 0.843 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.540 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.440 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.440 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.370 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.360 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.280 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.210 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.170 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.140 | Inavolisib | — uncovered |
| APOPTOSIS | 0.120 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.120 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.110 | Idelalisib | — uncovered |
| MYOGENESIS | 0.110 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.090 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |
| COAGULATION | 0.080 | Binimetinib | — uncovered |
| NOTCH_SIGNALING | 0.060 | Inavolisib | — uncovered |